Cervicogenic Headache, Cognitive Dysfunction

Frequency of Cognitive Dysfunction in Individuals With Cervicogenic Headache

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05572489

Enrollment

Registered

2022-10-07

Start date

2022-01-01

Completion date

2023-01-01

Last updated

2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervicogenic Headache

Brief summary

The goal of this study was to determine the frequency of cognitive dysfunction in patients with cervicogenic headache. participants will be asked questions to determine their cognitive status at once.

Detailed description

A set of survey-type questions will be asked to the participants. Pain and fatigue levels of the patients were measured by visual pain scale (VAS), mood states by Beck depression scale (BDI) and Pain catastrophizing scale (Pain catastrophizing scale), quality of life by Short Form-36 (SF-36), and cognitive status by Standard Mini. mental test (SMMT) and Montreal cognitive assessment scale (MOCA).

Interventions

DIAGNOSTIC_TESTvisual pain scale Beck depression scale Pain catastrophizing scale Short Form-36 Standard Mini mental test Montreal cognitive assessment scale

evaluation of pain, fatigue, mood, quality of life, cognitive status

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Inclusion criteria

Clinical Diagnosis of cervicogenic headache be over 18

Exclusion criteria

those under the age of 18 Those with neurological deficits Those with rheumatic diseases such as fibromyalgia, polymyalgia rheumatica, ankylosing spondylitis, rheumatoid arthritis Surgery in the cervical region in the past 6 months Those with widespread pain, significant pain in another anatomical location (eg, gonarthrosis) Those who use drugs or substances (alcohol, drugs, etc.) that may cause cognitive impairment Those with known neurological diseases such as cerebrovascular disease, MS, Parkinson's, dementia Those with major psychiatric illness Those with communication problems Those who have started psychiatric medical treatment in the last three months Those with significant hearing or vision problems Those with a history of uncontrollable systemic disease (cardiovascular, pulmonary, hepatic, renal, hematological, endocrine..)

Design outcomes

Primary

Measure	Time frame
cognitive status	01.12.2022

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026